GlassScriptPhysician profile
Mitra Ghasemi
NPI 1780720763
$838.29
in general payments reported to CMS, 2019-2025
12 companies · $49.41 in 2025
The $49.41 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.51 · 2022: $104 · 2023: $399 · 2024: $245 · 2025: $49.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651 · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.08 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $184.08 | 2021-2024 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $137.39 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $94.96 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $80.15 | 2024-2025 | Tezspire |
| Baxter Healthcare | $70.56 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $51.17 | 2022-2025 | Tezspire, Fasenra |
| Grifols USA, LLC | $46.12 | 2023-2024 | Prolastin-C Liquid |
| Abbvie INC. | $42.55 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.97 | 2023 | Glassia |
| United Therapeutics Corporation | $20.58 | 2021 | |
| Inogen, INC. | $19.22 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Ghasemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.